Alterity

Alterity Therapeutics (ATHE) reported new Phase 2 data showing ATH434 50 mg slowed functional decline by 52% versus placebo in multiple system atrophy after adjusting for baseline CSF NfL.

Alterity's ATH434 50 mg slowed MSA functional decline by 52% versus placebo in Phase 2..

ATH434 50 mg significantly slowed functional decline in MSA by approximately 52% versus placebo on the 11-item UMSARS at Week 52 with CSF NfL as a...

Alterity Therapeutics CEO David Stamler talked with Proactive at the ASX Small and Mid-Cap Conference about how it's developing disease modifying therapies, the neurodegenerative diseases market and what's next for the company.Alterity Therapeutics (ASX:

Detailed price information for Alterity Therapeutics Limited (PRNAF) from The Globe and Mail including charting and trades.

Detailed price information for Alterity Therapeutics Ltd ADR (ATHE-Q) from The Globe and Mail including charting and trades.

ATH434 50 mg significantly slowed functional decline in MSA by approximately 52% versus placebo on the 11-item UMSARS at Week 52 with CSF NfL as a covariate Baseline CSF NfL predicted the rate of functional

The most you can lose on any stock (assuming you don